Nuvalent has announced that the FDA has accepted the New Drug Application (NDA) for neladalkib, an investigational ALK-selective inhibitor, for the treatment of patients with TKI-pretreated advanced ALK-positive non-small cell lung cancer (NSCLC). The submission was supported by pivotal data from the ALKOVE-1 Phase 1/2 clinical trial, with a PDUFA date set for November 2026.

Clinical Takeaway

The FDA acceptance of neladalkib’s NDA represents a significant advancement for patients with TKI-pretreated ALK-positive NSCLC, addressing a critical unmet need in this population. The drug demonstrated encouraging overall activity including intracranial responses and the ability to address key drivers of disease progression, with a generally well-tolerated safety profile consistent with its ALK-selective, TRK-sparing design.

Drug Profile & Mechanism

  • Agent: Neladalkib (investigational)
  • Class: ALK-selective tyrosine kinase inhibitor
  • Design: ALK-selective, TRK-sparing inhibitor designed to address resistance mutations and brain metastases
  • Developer: Nuvalent, Inc.

Target Population

  • Primary indication: TKI-pretreated patients with advanced ALK-positive NSCLC
  • Specific populations served:
    • Patients whose disease progresses with brain metastases
    • Patients with resistance mutations
    • Patients unable to tolerate currently available TKIs
  • Future development: Phase 3 ALKAZAR trial investigating neladalkib vs alectinib in TKI-naïve patients

Study Design

  • Trial name: ALKOVE-1
  • Design: Global, single-arm Phase 1/2 clinical trial
  • Status: Registration-directed study
  • Data presentation: Pivotal TKI-pretreated data presented at ASCO 2026
  • Initial announcement: Pivotal data initially announced November 2025

Efficacy Outcomes

Key efficacy findings from the ALKOVE-1 trial in TKI-pretreated patients included:

  • Overall activity: Encouraging overall response activity demonstrated
  • Intracranial responses: Notable activity against brain metastases
  • Resistance mechanisms: Ability to address key drivers of disease progression
  • Consistency: Data build on consistent characterization across preclinical and Phase 1 investigations

Safety Profile

  • Tolerability: Generally well-tolerated safety profile observed
  • Design advantage: Safety profile consistent with ALK-selective, TRK-sparing design
  • Patient population: Profile suitable for patients unable to tolerate currently available TKIs

Regulatory Timeline

  • NDA submission: April 2026
  • FDA acceptance: Confirmed
  • PDUFA date: November 2026
  • Indication: TKI-pretreated advanced ALK-positive NSCLC

Key Clinical Implications

✔ Addresses unmet need in TKI-pretreated ALK-positive NSCLC patients with resistance or intolerance to current therapies

✔ Demonstrates activity against brain metastases, a common site of disease progression in ALK-positive NSCLC

✔ ALK-selective, TRK-sparing design may offer improved tolerability compared to existing options

✔ Potential to move up treatment paradigm based on ongoing Phase 3 ALKAZAR trial in TKI-naïve patients

Bottom Line

The FDA acceptance of neladalkib’s NDA represents a major milestone for patients with TKI-pretreated ALK-positive NSCLC. With its ALK-selective, TRK-sparing design and demonstrated activity against brain metastases and resistance mutations, neladalkib has the potential to address significant unmet needs in this challenging patient population. The November 2026 PDUFA date provides a clear timeline for potential approval, while ongoing development in TKI-naïve patients through the Phase 3 ALKAZAR trial may further expand its therapeutic impact in ALK-positive NSCLC.

Sources: